Novel therapeutics for personalized medicine

CatenaBio develops novel therapeutics by forming never-before-possible structures, which can modify and combine proteins with ease.


FUND I
Rewriting biology for new possibilities

Constructive Bio combines world-leading genome synthesis and engineered translation technologies to unlock enhanced organisms and create next-gen protein therapeutics, biopolymers, and materials.
FUND I
Rejuvenating cells

Turn.bio is developing mRNA medicines formulated to instruct specific cells in the body to fight disease or repair damaged tissue.
FUND I
First ever on-demand potassium monitoring

ProtonIntel is developing a continuous wearable kidney health monitoring platform, an innovation with the potential to transform patient care in critical medical scenarios.
FUND I
Therapeutics to preserve biological youth

Rubedo Life Sciences is developing therapeutics to target senescent cells that contribute to age-related diseases.


FUND I
A new logic to treating cancer cells

Valink Therapeutics is developing a series of novel therapeutics that are more effective at attacking tumours, while sparing healthy tissue.
FUND I
New understanding of biology and diseases

Glyphic Biotechnologies is developing a protein sequencing platform that can decode the human proteome using single-molecule, massively parallel technology.
FUND I
Funding the future of longevity research

The Longevity Science Foundation is an international non-profit funding early-stage research on extending the healthy human lifespan.


FUND I
Reversing skin ageing

Medici Therapeutics deploys genetic solutions to solve skin ageing at the molecular level.

FUND I

portfolio companies

We are curating an ecosystem of biotech and longevity-focused companies ready to change the world. We facilitate connections for the companies we invest in, linking them with forward-thinking leaders and readily available growth prospects to drive their advancement.

Discovering new drugs with AI

Insilico Medicine applies generative AI to discover new treatments for COVID-19, pulmonary disease and other conditions.
FUND I
Pioneering pet longevity

Basepaws. Different breeds, different needs. Every cat is unique. Get to know your cat's health and behavior better with a feline DNA Test.
FUND I
Measuring your biological age

Deep Longevity provides a SaaS solution integrating multiple biomarkers of aging dubbed "deep aging clocks" to provide a comprehensive and universal measure of human biological age.
FUND I
Engaging patients in clinical trials

Longenesis builds software that makes it easier for patients and study organizers to collect, analyze, and manage medical data.
FUND I
Powering the longevity industry

First Longevity brings together innovators and investors to support the companies that will form the longevity economy. Longevity.Technology is the industry's leading media outlet.
FUND I
Detecting ovarian cancer with blood tests

AOA Dx is developing the first accurate early-stage non-invasive ovarian cancer diagnostic test that will improve clinical practice, reduce patient mortality and deliver cost savings.
FUND I
Personalizing cancer treatments

PreComb leverages artificial intelligence to test cancer treatments on genetically identical tumor sample twins.
FUND I
Improving newborn infection diagnosis

Melio provides an advanced diagnostic platform to detect pathogens faster and more effectively than existing solutions.


FUND I
Delivering new mental health approaches

Freedom Biosciences
is developing cutting-edge ketamine therapies for treatment-resistant depression.
FUND I
Unlocking your personal health

SiPhox Health provides cutting-edge at-home health testing offering insights into cardiovascular health, metabolism, hormones, and more.


FUND I
Powering AI-enabled analytics for skincare

Haut.AI
offers personalized wellness tools that empower users to make better skin and body health choices.


FUND I
Personalised bioactive compounds

Ani Biome is a longevity startup pursuing a microbiome-centric approach through personalized bioactive supplements .


FUND I
Leveraging bacteria for drug discovery

Interface Biosciences is a drug discovery company developing platform to identify metabolites derived from microorganisms to treat a range of diseases, starting from atopic dermatitis.
FUND I
Unlocking undruggable targets

Unnatural Products is pairing ML with chemistry and leveraging the power of macrocycles to create treatments for undruggable or hard-to-reach drug targets.


FUND I
Advanced mRNA platform

Helix Nanotechnologies is building the world's most advanced mRNA platform to enable previously impossible applications across human and non-human biology.


FUND I
Advancing the longevity industry

The Longevity Biotech Association is a consortium aiming to advance the longevity industry by setting standards, educating stakeholders, and encouraging partnerships.


FUND I
Precision therapies engineered for change

Trogenix develops precision cancer treatments that selectively target diseased cell states and behavior, combining payloads that reveal cancer to the body’s immune system and kill tumor cells.


FUND II
Washington D.C., US

The Future Belongs to Biotech Founders
© All Rights Reserved, 2025
get in touch
social
newsletter